Trump's 100 per cent tariff on branded drugs challenges India's pharma exporters but opens doors for growth in generics and biosimilars

By now, the world has become accustomed to the whimsical ways of United States President Donald Trump. The maverick Republican has come up with another policy shock: imposition of a 100 per cent tariff on branded or patented pharmaceutical products. India, a major pharma exporter, will have to bear the brunt of the consequences. Until now, pharma exports were exempt from the 50 per cent tariffs imposed by the Trump administration on Indian goods. This would change now. The latest tariff move is a wake-up call for global pharma exporters as it signals a shift toward protectionism that could reshape future access. Expectedly, the Nifty Pharma index, designe

See Full Page